Expression and secretion of human glucocerebrosidase mediated by recombinant lentivirus vectors in vitro and in vivo: implications for gene therapy of Gaucher disease
- 28 May 2004
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 318 (2) , 381-390
- https://doi.org/10.1016/j.bbrc.2004.04.040
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesisThe Lancet, 2000
- Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant SourcesAnnals of Internal Medicine, 1995
- The Role of Neurogenetics in Gaucher DiseaseArchives of Neurology, 1993
- Toward Gene Therapy for Gaucher DiseaseHuman Gene Therapy, 1991
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991
- Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease.Proceedings of the National Academy of Sciences, 1990
- Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.Proceedings of the National Academy of Sciences, 1990
- Expression of human glucocerebrosidase in murine long-term bone marrow cultures after retroviral vector-mediated transferBlood, 1990
- The Biogenesis of LysosomesAnnual Review of Cell Biology, 1989
- Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease.Journal of Clinical Investigation, 1966